Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results
On February 25, 2025, the Company announced positive 12-week data from the sixth cohort of the ongoing RESOLVE trial in patients with eosinophilic esophagitis ('EoE') noting no adverse events and continued positive data on efficacy and safety outcomes as well as further evidence of improved patient responses with higher dosing levels.
'We recently achieved a significant clinical milestone with the release of positive nine-month data from our ongoing open-label, dose-escalation Phase 1b/2a RESOLVE trial, which continue to support EP-104GI as a potentially transformative therapy for eosinophilic esophagitis,' said Dr. James Helliwell, Chief Executive Officer of Eupraxia. 'The sustained or improved treatment outcomes observed over a nine-month period after a single treatment with 48mg dose of EP-104GI is a promising finding in the treatment of EoE with an injectable delivery system. We believe these results provide further evidence of the precision and durability of our DiffuSphere™ technology and provide a strong foundation as we advance into higher-dose cohorts in the coming quarters.'
VICTORIA, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ('Eupraxia' or the 'Company') (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the first quarter of 2025. All dollar values are in U.S. dollars unless stated otherwise.
Story continues
The Company had cash of $27.5 million as of March 31, 2025, down from $33.1 million at the end of the fourth quarter of 2024. These funds are being used to fund clinical trials in EP-104 and the remainder of the funds will be used for general and administrative expenses, working capital needs and other general corporate purposes.
The Company anticipates that existing cash reserves, and proceeds from the future exercise of in-the-money warrants, will be sufficient to fund the Company to the third quarter of 2026.
As of March 31, 2025, the Company had 35,849,353 common shares and 8,905,638 preferred shares outstanding.
Potential Impact of Tariffs
Management continues to monitor the North American trade situation stemming from the February 2025 announcement by the U.S. government of proposed 25% tariffs on selected imported Canadian goods, and the subsequent Canadian announcement of planned retaliatory tariffs on selected imported U.S. goods.
Eupraxia manufactures its clinical supplies of EP-104IAR and EP-104GI in the U.S. by a third-party. The Company expects to continue to access manufactured products from the U.S.
The Company maintains U.S. dollar balances to pay U.S. dollar expenses and to minimize the impact of short-term fluctuations in exchange rates.
Management continues to assess the potential direct and indirect impacts of tariffs, counter-tariffs and other trade protection measures on Eupraxia's business and will take those steps it deems necessary to attempt to mitigate any impact as the situation evolves.
Financial Statements and Management Discussion & Analysis
Please see the unaudited interim consolidated financial statements and related MD&A for more details. The unaudited interim consolidated financial statements for the quarter ended March 31, 2025, and related MD&A have been reviewed and approved by Eupraxia's Audit Committee and Board of Directors. For a more detailed explanation and analysis, please refer to the MD&A that has been filed under the Company's profile on EDGAR at www.sec.gov and on SEDAR+ at sedarplus.ca and which is also available on the Company's website at www.eupraxiapharma.com.
About Eupraxia Pharmaceuticals Inc.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the DiffuSphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.
Eupraxia's EP-104GI is currently in a Phase 1b/2a trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com.
Notice Regarding Forward-looking Statements and Information
This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "suggests", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the Company's product candidates, including their expected benefits to patients with respect to safety, tolerability, efficacy and duration; the results gathered from studies and trials of Eupraxia's product candidates; the advancement toward higher dose cohorts and timing thereof; the potential for the Company's technology to impact the drug delivery process; potential market opportunity for the Company's products; potential pipeline indications; expectations regarding the funding of the Company's operations to the third quarter of 2026, and the use of cash reserves and proceeds, including from the potential exercise of warrants; and expectations regarding continued access to both API and manufactured products from the U.S., as well as ongoing monitoring and necessary actions to attempt to mitigate any impact of tariffs, counter-tariffs and other trade protection measures on the Company's business. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its products and services; the potential impact of tariffs on the cost of the Company's API and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.
For investor and media inquiries, please contact:
Danielle Egan, Eupraxia Pharmaceuticals Inc.
778.401.3302
degan@eupraxiapharma.com
or
Kevin Gardner, on behalf of:
Eupraxia Pharmaceuticals Inc.
617.283.2856
kgardner@lifesciadvisors.com
SOURCE Eupraxia Pharmaceuticals Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
CleanTech Engages Senergy for Digital Marketing
Vancouver, British Columbia--(Newsfile Corp. - August 1, 2025) - CleanTech Vanadium Mining Corp. (TSXV: CTV) (OTCQB: CTVFF) ("CleanTech" or the "Company") announces that it has retained Senergy Communications Capital Inc. ("Senergy") to provide digital media and marketing services. Senergy is a digital marketing firm that will assist with on-line communications and strategies with the goal of increasing awareness of the Company and its projects. The nature and platform of the promotional activity will be digital marketing and advertising, influencer marketing, native advertising in Germany and media program management and coordination. In consideration for these services, the Company has agreed to pay Senergy a one-time upfront fee of $75,000 plus GST for a two-week campaign commencing August 11, 2025, and ending August 25, 2025. Aleem Fidai of Unit 228, 1122 Mainland St., Vancouver, BC, is the founder and chief executive officer of Senergy and may be contacted at 778-772-6740 or aleem@ To the Company's knowledge, neither Senergy nor Mr. Fidai has any interest, directly or indirectly, in the Company or its securities or any right or intent to acquire such an interest. About CleanTech Vanadium Mining Corp. CleanTech is an exploration-stage mining company focused on vanadium and critical mineral resources. The Company owns a 100% interest in the Gibellini vanadium project in Nevada, United States. Further information on CleanTech can be found at CLEANTECH VANADIUM MINING CORP. ON BEHALF OF THE BOARD John LeeChief Executive Officer For more information about CleanTech, please contact: Suite 1008 – 409 Granville StreetVancouver, BC V6C 1T2Phone: 1.877.664.2535Email: info@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Sign in to access your portfolio
Hamilton Spectator
20 minutes ago
- Hamilton Spectator
Moe disappointed by Trump's tariffs but says Carney should remove countermeasures
SASKATOON - Saskatchewan Premier Scott Moe says Prime Minister Mark Carney should start removing counter tariffs against the United States to get a deal done with President Donald Trump. U.S Commerce Secretary Howard Lutnick has asked Ottawa to do away with countermeasures, and Moe says Canada should heed the advice. 'If we're serious about achieving a renewed, revamped and enhanced trade environment or some type of a new and improved (Canada-United States-Mexico trade agreement), somebody's going to have to move in this space,' Moe said Friday at a news conference. 'We would suggest that it should be Canada.' Trump followed through late Thursday on his threat to hit Canada with 35 per cent tariffs — up from 25 per cent — on goods not compliant with the trade agreement, better known as CUSMA. Tariffs of 50 per cent remain in effect on steel and some copper products, and levies on Canadian automobiles and lumber are also in place. Carney has imposed 25 per cent tariffs on $30 billion in U.S. goods. Moe said he's heard from farmers dinged by Canadian levies on steel bins, as it's importers pay those tariff charges. 'The reason we will be urging for a reduction of counter tariffs is they hurt Saskatchewan and Canadians, our families, our businesses and our places of work,' he said. '(It's) in the same way that Donald Trump's tariffs are pushing up the cost of doing business in the U.S. and really pushing them into a situation where the last two months running, their job numbers have been much more dismal than the projection.' Moe also called the jump in Trump's tariffs disappointing. He said he gives credit to Canada-U.S. Trade Minister Dominic LeBlanc for ensuring exports compliant with CUSMA are tariff-free. Under the agreement, 95 per cent of Saskatchewan exports move into the United States without duties, Moe added. 'That is incredibly important,' the premier said. '(It) allows us largely to have an opportunity to create North American energy security, food security and manufacturing security.' U.S. Census Bureau data shows nearly 60 per cent of Canadian goods that entered the country in May were compliant with the agreement. Moe and other premiers have also called on Ottawa to cut regulations to spur pipeline and rail development. He said he's hopeful Carney's latest law to streamline approvals for national infrastructure projects will do just that. Meanwhile, Alberta Premier Danielle Smith said the vast majority of her province's products remain tariff-free, because they also fall under the trade agreement. Smith said in a social media post it's unfortunate non-compliant goods will be hit with the higher tariffs. 'These tariffs hurt both Canadian and American businesses and workers, and they weaken one of the most important trade and security alliances in the world,' she said. 'I remain convinced that the path to a positive resolution with our U.S. partners lies in strong, consistent diplomacy and a commitment to working in good faith toward shared priorities.' Smith said Carney should continue negotiating with Trump, while working toward diversifying the country's economy. Both Moe and Smith recently reallowed U.S. liquor to be sold in their provinces, after temporarily banning such sales when the tariff war started earlier this year. Moe has said the 'elbows-up' approach in dealing with Trump is nothing more than a slogan. 'This is a time for us ... to make fact-based decisions, not to make decisions that maybe make us feel good, that we think are going to be good slogans or things of that nature,' he said Friday. This report by The Canadian Press was first published Aug. 1, 2025. — By Jeremy Simes in Regina Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
New York Times
21 minutes ago
- New York Times
192,000 Play Kitchens Are Recalled After Child Dies of Strangulation
About 192,000 children's play kitchens that pose 'a risk of serious injury or death' are being recalled after the shirt of a 23-month-old boy got caught on one of its hooks and he asphyxiated, the U.S. Consumer Product Safety Commission said this week. The play kitchens, which were marketed as the KidKraft Farm to Table Model Play Kitchens, have three hooks intended to hang accessories. They can pose a strangulation and asphyxia hazard, the commission said. According to the recall notice from the commission, issued in conjunction with Canada's health agency, Health Canada, children who crawl onto the kitchen set could get caught on the hooks and asphyxiate or suffocate themselves. The product was sold by Backyard Kids of Plano, Texas, and previously KidKraft. In a statement, KidKraft said safety is its 'first priority.' It warned customers of the danger, adding that they 'should immediately stop using the recalled play kitchens.' Anyone who owns the kitchen toy set should remove the hooks and contact Backyard Kids for free replacement hooks, the consumer agency and the brand's statement said. A representative for Backyard Kids could not be immediately reached on Friday. A photo released with the recall shows a children's kitchen with a small fridge, sink and oven measuring 43 inches tall and 44 inches long. The area behind the sink and oven is backless with a rod that holds three hooks meant to hold play pots and pans. The promotional image for the product shows some toy kitchen utensils hanging from it. In February 2023, the clothing of the 23-month-old boy in Oregon got snagged on one of the hooks leading to his death, the commission said. The recalled kitchens were sold online at and from 2018 through July 2025. The model number 53411 is found on a sticker on the back of the play set, the commission said. KidKraft filed for bankruptcy in 2024, the commission said. KidKraft is a brand under Backyard Kids, according to the company's website. More information about the recall is available on the company's website.
